AmbioPharm - Crunchbase Company Profile & Funding

Q: Who invested in AmbioPharm?

AmbioPharm has 2 investors including The Carlyle Group And MVM Life Science Partners.

Q: When was the last funding round for AmbioPharm?

AmbioPharm closed its last funding round on obfuscated from a Private Equity round.

Q: How much funding has AmbioPharm raised to date?

AmbioPharm has raised obfuscated.

Overview

AmbioPharm

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About AmbioPharm

CB Rank

37863

AmbioPharm is a manufacturer of active pharmaceutical ingredients and generic peptides.

Acquired by

CordenPharma

Founded

obfuscation

Private

Private Equity

North Augusta, South Carolina, United States

51-100

ambiopharm.com

Biotechnology

Innovation Management

Manufacturing

Funding Rounds

Private Equity

OBF

obfuscation

Venture - Series Unknown

OBF

obfuscation

Key People

Robert Geiger: Senior Vice President Business Development
Past Role: AmbioPharm, Vice President and Co-founder
Mark DaFonseca: Executive Vice President of Global Business Development and Sales
Past Role: CoreRx, Executive Director & Chief Business Officer

Details

Legal Name

AmbioPharm, Inc.

Also Known As

APi

Operating Status

Active

Company Type

For Profit

Founders

Robert Geiger

About the Company

AmbioPharm is a manufacturing company that manufactures active pharmaceutical ingredients and generic peptides. It undertakes development and production of research-grade complex peptide generic pharmaceuticals and active pharmaceutical ingredients for pre-clinical in-vitro, medicinal, and toxicology programs through its responsive business model

and rapid manufacturing processes that enable pharmaceutical and biotech companies to take their peptide projects from preclinical and clinical to commercial quickly at lower costs.

Phone Number

(415) 921-3593

Contact Email

generics@ambiopharm.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Key Employee Changes

Products & Services

Contract GMP Peptide Manufacturing

Manufacturing of peptide-based active pharmaceutical ingredients (APIs) under cGMP conditions using solid-phase, solution-phase, or hybrid peptide synthesis methods.

Research-Grade Peptide Supply

Provision of research-grade peptides for pre-clinical in vitro studies, medicinal efficacy, and toxicology programs in milligram to multi-gram quantities.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Private Equity Round - AmbioPharm	1	obfuscated obfuscation	The Carlyle Group	Private Equity
obfuscated obfuscation	Private Equity Round - AmbioPharm	1	obfuscated obfuscation	The Carlyle Group	Private Equity
obfuscated obfuscation	Private Equity Round - AmbioPharm	1	obfuscated obfuscation	The Carlyle Group	Private Equity
obfuscated obfuscation	Private Equity Round - AmbioPharm	1	obfuscated obfuscation	The Carlyle Group	Private Equity
obfuscated obfuscation	Private Equity Round - AmbioPharm	1	obfuscated obfuscation	The Carlyle Group	Private Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Private Equity Round - AmbioPharm	1	obfuscated obfuscation	The Carlyle Group	Private Equity
obfuscated obfuscation	Private Equity Round - AmbioPharm	1	obfuscated obfuscation	The Carlyle Group	Private Equity
obfuscated obfuscation	Private Equity Round - AmbioPharm	1	obfuscated obfuscation	The Carlyle Group	Private Equity
obfuscated obfuscation	Private Equity Round - AmbioPharm	1	obfuscated obfuscation	The Carlyle Group	Private Equity
obfuscated obfuscation	Private Equity Round - AmbioPharm	1	obfuscated obfuscation	The Carlyle Group	Private Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
The Carlyle Group	Yes	Private Equity Round - AmbioPharm	—
The Carlyle Group	Yes	Private Equity Round - AmbioPharm	—
The Carlyle Group	Yes	Private Equity Round - AmbioPharm	—
The Carlyle Group	Yes	Private Equity Round - AmbioPharm	—
The Carlyle Group	Yes	Private Equity Round - AmbioPharm	—

M&A Details

AmbioPharm

was acquired by

CordenPharma

obfuscation

Transaction Name

AmbioPharm acquired by CordenPharma

Acquired by

CordenPharma

Announced Date

obfuscation

Market Intelligence

People

View Profiles & Contacts

Headcount

51-100

Employee Profiles

Contacts

158

Employee Profiles

Robert Geiger Senior Vice President Business Development
Mark DaFonseca Executive Vice President of Global Business Development and Sales
Brian Gregg Chief Executive Officer and Board Member
Tim Nieters Chief Operations Officer